Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC

Summary

XELOX as first-line treatment regimen has limited efficacy against patients with metastatic colorectal cancer (mCRC). Peritoneal metastasis is one of the most lethal factor for mCRC. Intraperitoneal chemotherapy has became a widely accepted strategy in the treatment of peritoneal dissemination. We hypothesized that combined multi-channel administration, such as intraperitoneal chemotherapy, oral chemotherapy, and intravenous chemotherapy, can produce better results than XELOX for first-line treatment for mCRC patients.

Timeline

Start

2016-01-01

Primary completion

2019-12

Completion

2020-12

Drugs

Indications